stockrowPharming Group N.V. Sponsored ADR
PHAR Healthcare Biotechnology
Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024.
- Revenue
- +20.9%
- EPS
- +190.9%
- Free cash flow
- +0.42%
- Total debt
- +1.61%
Quarter to September 2026, against a year earlier
Follow PHAR
Alert me
Pharming Group N.V. Sponsored ADR (PHAR) P/E ratio
As of 6 November 2026, Pharming Group N.V. Sponsored ADR (PHAR) trades at a P/E ratio of 34.2×. Over the past ten years it has ranged from 0.0× (September 2025) to 1,809× (December 2025); the current reading is higher than 44% of that period. That is above the Biotechnology industry median of 10.6× and above the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 442× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 60.7× | (3.59%) |
| FY2021 | 63.0× | (18.51%) |
| FY2020 | 77.3× | (4.26%) |
| FY2019 | 80.8× | 0.00% |
| FY2018 | 80.8× | 0.00% |
| FY2017 | 80.8× | 0.00% |
| FY2016 | 80.8× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 27.8× | (70.03%) |
| Jun 2026 | 92.6× | 5.73% |
| Mar 2026 | 87.6× | (80.17%) |
| Dec 2025 | 442× | (69.53%) |
| 24 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GLUE Monte Rosa Therapeutics, Inc. compare | n/m |
| ANRO Alto Neuroscience, Inc. compare | n/m |
| ORIC Oric Pharmaceuticals, Inc. compare | n/m |
| JBIO Jade Biosciences, Inc. compare | n/m |
| IVA Inventiva S.A. Sponsored ADR compare | n/m |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.4× |
| PHAR Pharming Group N.V. Sponsored ADR | 34.2× |
| LTGO Latigo Biotherapeutics Inc compare | — |
| CTY City Therapeutics, Inc compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)